SCALE Obesity Trial: A Plain-English Overview of What It Established

At a glance

| Parameter | Detail | |-----------|--------| | N | 3,731 (2:1 randomization; 2,487 liraglutide, 1,244 placebo) | | Intervention | Liraglutide 3.0 mg subcutaneous injection daily | | Comparator | Matched placebo injection daily | | Duration | 56 weeks | | Primary endpoint | Change in body weight from baseline (%) | | Key result | −8.0% liraglutide vs −2.6% placebo (estimated treatment difference −5.4 percentage points, p < 0.001) | | Population | Adults with BMI ≥30, or BMI ≥27 with dyslipidemia or hypertension, without diabetes | | Background therapy | All participants received diet (−500 kcal/day deficit) and exercise (≥150 min/week) counseling |

The Question SCALE Asked

Before 2015, physicians had very few drug options for patients with obesity who had already tried lifestyle changes alone. Orlistat blocked fat absorption but caused gastrointestinal side effects that limited adherence. Phentermine-topiramate worked but carried cardiovascular and teratogenicity concerns. The GLP-1 receptor agonist liraglutide was already approved at 1.8 mg for type 2 diabetes (as Victoza), where modest weight loss had been observed as a secondary benefit.

SCALE asked a direct question: if you give a higher dose of liraglutide (3.0 mg) specifically to people with obesity but without diabetes, does it produce clinically meaningful weight loss over one year when added to standard lifestyle counseling?

Who Got In (and Who Didn't)

The trial enrolled adults aged 18 or older across 191 sites in 27 countries. Inclusion required a BMI of 30 or above, or a BMI of 27 or above with treated or untreated dyslipidemia or hypertension.

Critical exclusion criteria included type 1 or type 2 diabetes, prior bariatric surgery, use of other weight-loss medications within the previous 90 days, and a history of pancreatitis. Participants also needed a stable body weight (defined as <5 kg self-reported change in the previous 90 days).

The enrolled population was predominantly white (85%), female (79%), with a mean age of 45 years and mean baseline BMI of 38.3 kg/m². About 61% met criteria for prediabetes at screening. This matters for generalizability: the trial population skewed toward middle-aged white women with class II obesity and metabolic risk.

What Participants Actually Experienced

Every participant received the same lifestyle intervention: dietary counseling targeting a 500 kcal/day deficit from estimated maintenance energy expenditure, plus encouragement to walk at least 150 minutes per week. This was not a token gesture. Dietitians met with participants roughly monthly.

The SCALE Treatment Protocol: Dose Escalation and Maintenance

The liraglutide arm started at 0.6 mg daily and escalated by 0.6 mg each week until reaching the target of 3.0 mg at week 5. This slow escalation was designed to reduce nausea, the most common GLP-1 side effect. Participants self-injected subcutaneously (abdomen, thigh, or upper arm) once daily at any time, independent of meals.

The placebo arm followed an identical injection schedule with matched pens. Both groups maintained their lifestyle intervention throughout. Neither participants nor investigators knew which injection they were receiving.

What Was Measured and How

The trial had three co-primary endpoints, all assessed at week 56:

1. Percentage change in body weight from baseline
2. Proportion achieving ≥5% weight loss
3. Proportion achieving >10% weight loss

The 5% and 10% thresholds are not arbitrary. The FDA guidance for obesity drugs specifies that a drug should demonstrate either a mean weight loss of at least 5% greater than placebo, or that a significantly greater proportion of drug-treated patients achieve at least 5% weight loss compared to placebo. SCALE was designed to hit both benchmarks.

Secondary endpoints included changes in waist circumference, BMI, glycemic parameters, blood pressure, lipid profiles, and patient-reported quality of life (Impact of Weight on Quality of Life-Lite questionnaire).

The Results in Detail

Weight Loss

| Outcome | Liraglutide 3.0 mg | Placebo | Difference | |---------|-------------------|---------|------------| | Mean weight change (%) | −8.0% | −2.6% | −5.4 pp (p < 0.001) | | Mean weight change (kg) | −8.4 kg | −2.8 kg | −5.6 kg | | Achieved ≥5% loss | 63.2% | 27.1% | OR 3.9 (p < 0.001) | | Achieved >10% loss | 33.1% | 10.6% | OR 4.0 (p < 0.001) | | Achieved >15% loss | 14.4% | 3.5% |, |

The weight loss was not front-loaded and then regained. Participants in the liraglutide arm continued losing weight through approximately week 40, then largely maintained through week 56. The placebo response of 2.6% loss reflects what structured lifestyle counseling alone achieves in a trial setting.

Cardiometabolic Parameters

Liraglutide produced clinically relevant improvements beyond weight alone. Systolic blood pressure dropped by 4.2 mmHg vs 1.5 mmHg with placebo. Fasting glucose fell by 7.1 mg/dL vs 0.8 mg/dL. Among participants with prediabetes at baseline, 69.2% in the liraglutide group reverted to normoglycemia at week 56, compared with 32.7% on placebo.

Lipid changes were more modest. Total cholesterol, LDL, and triglycerides improved slightly with liraglutide. HDL did not change significantly.

Adverse Events

| Event | Liraglutide | Placebo | |-------|-------------|---------| | Nausea | 40.2% | 14.7% | | Diarrhea | 21.2% | 10.5% | | Constipation | 19.6% | 8.5% | | Vomiting | 16.3% | 4.0% | | Injection-site reaction | 13.9% | 10.6% | | Gallbladder events | 2.5% | 1.0% | | Pancreatitis (adjudicated) | 0.2% (n=5) | 0 |

Gastrointestinal symptoms were the dominant tolerability issue. Most nausea occurred during dose escalation (weeks 1-5) and was rated mild-to-moderate. Still, 9.9% of liraglutide participants discontinued due to adverse events vs 3.8% on placebo. The nausea-driven dropout is clinically important because it means the per-protocol population was enriched for tolerators, potentially inflating efficacy estimates slightly.

The gallbladder signal (cholelithiasis, cholecystitis) at 2.5% vs 1.0% is consistent with rapid weight loss from any cause. Five cases of pancreatitis occurred in the liraglutide arm vs zero on placebo. The FDA label for Saxenda includes pancreatitis as a warning based partly on this signal.

Limitations the Authors Acknowledged

The trial investigators were transparent about several issues:

Dropout rate. Roughly 25% of participants did not complete 56 weeks. The primary analysis used a mixed model for repeated measures (MMRM), which assumes data are missing at random. A supplementary analysis using last observation carried forward yielded slightly smaller treatment effects, suggesting some bias from differential dropout.

Duration. Fifty-six weeks is long enough to demonstrate efficacy, but obesity is a chronic condition. What happens when the drug stops? A subsequent extension study (SCALE Maintenance) showed that discontinuing liraglutide after initial weight loss led to regain, confirming this is a maintenance therapy rather than a cure.

Population homogeneity. The 85% white, 79% female enrollment limits confidence in generalizing to men and non-white populations. Response heterogeneity by sex and ethnicity was not powered to detect.

Lifestyle intervention intensity. Monthly dietitian visits and structured calorie targets exceed what most primary care practices can deliver. Real-world weight loss may be smaller if the lifestyle backbone is less rigorous.

What Changed Because of SCALE

The FDA approved liraglutide 3.0 mg (branded Saxenda) for chronic weight management in December 2014, based primarily on this trial plus two other SCALE studies (in diabetes and in maintenance). It became the first GLP-1 receptor agonist approved specifically for obesity.

The 2016 Endocrine Society guidelines incorporated liraglutide 3.0 mg as a pharmacotherapy option for adults with BMI ≥30 or BMI ≥27 with comorbidities who have not achieved target weight loss with lifestyle alone. This recommendation stood until semaglutide 2.4 mg (Wegovy) arrived in 2021 with larger effect sizes from the STEP trials.

Today, liraglutide 3.0 mg remains available but has largely been overtaken in clinical preference by once-weekly semaglutide, which produces roughly twice the weight loss (about 15% in the STEP 1 trial). SCALE's lasting contribution is that it validated the GLP-1 mechanism as a viable obesity treatment pathway and established the regulatory and clinical framework through which all subsequent GLP-1 obesity drugs have been evaluated.

Putting the Numbers in Context

An 8% mean weight loss may sound modest compared to bariatric surgery (20-35%) or newer agents like tirzepatide (20-25%). But context matters. SCALE was conducted in a population that had already struggled with lifestyle-only approaches. The placebo arm's 2.6% loss shows what dietitian visits and exercise goals achieve without pharmacologic help. The additional 5.4 percentage points from liraglutide translated to clinically relevant improvements in blood pressure, glycemia, and prediabetes reversion.

For the individual patient, the averages obscure important variability. One-third of participants lost more than 10%, while about 37% did not reach the 5% threshold. Early response predicted later success: the prescribing information recommends discontinuing if a patient has not lost at least 4% of body weight by 16 weeks, since continued treatment is unlikely to produce meaningful results in non-responders.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. https://pubmed.ncbi.nlm.nih.gov/26132939/
2. FDA. Saxenda (liraglutide) injection prescribing information. 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf
3. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss (SCALE Maintenance). Int J Obes. 2013;37(11):1443-1451. https://pubmed.ncbi.nlm.nih.gov/26670557/
4. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362. https://pubmed.ncbi.nlm.nih.gov/26544531/
5. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/